Evidence map›Paper›PMID 32872000›Full record

ArticleMedicine2020

Examination of pain relief effect of Goreisan for glossodynia.

Takao Ayuse, Ichiro Okayasu, Mizuki Tachi-Yoshida, Jun Sato, Hironori Saisu, Masahiko Shimada, Yoko Yamazaki, Hiroko Imura, Naoki Hosogaya, Sawako Nakashima

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Takao AyuseDivision of Clinical Physiology, Department of Translational Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences.ORCID 0000-0002-6202-1312
Ichiro OkayasuDivision of Clinical Physiology, Department of Translational Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences.
Mizuki Tachi-YoshidaDepartment of Dental Anesthesiology, Nagasaki University Hospital, Nagasaki.
Jun SatoAichi Medical University, Nagoya.
Hironori SaisuAichi Medical University, Nagoya.
Masahiko ShimadaOrofacial Pain Clinic, Tokyo Medical and Dental University Dental Hospital, Tokyo.
Yoko YamazakiOrofacial Pain Clinic, Tokyo Medical and Dental University Dental Hospital, Tokyo.
Hiroko ImuraOrofacial Pain Clinic, Tokyo Medical and Dental University Dental Hospital, Tokyo.
Naoki HosogayaNagasaki University Hospital, Clinical Research Center, Nagasaki, Japan.
Sawako NakashimaNagasaki University Hospital, Clinical Research Center, Nagasaki, Japan.
Nagasaki University Hospital · JPTokyo Medical and Dental University Hospital · JPAichi Medical University · JPNagasaki University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPain in glossodynia may be severe; it may prevent patients from working, interfere with daily life activities, and necessitate a patient's visit to a medical institution for consultation and treatment. The pain may be described as persistent and burning (tingling, tingling) or stinging. Patients may complain of dry mouth (dryness), which is thought to cause inflammation of the tongue and gingival mucous membranes and increased pain. Medications are prescribed based on the symptoms of glossodynia, and the therapeutic effect is confirmed. However, each drug has side effects, for example, pain may reduce, but drowsiness and dizziness may occur; further, there is always a tendency of drowsiness.On the other hand, Goreisan, a Chinese herbal medicine, has already been used by physicians to treat pain in the oral and maxillofacial regions resulting from rapid changes in air pressure. However, the lack of high-quality clinical research has been of concern, and a randomized clinical trial to investigate the efficacy and safety of Goreisan for treatment of pain in glossodynia is warranted. METHODS/

designThis multicenter, randomized, controlled study will involve patients treated for glossodynia-related pain. In the experimental group, Goreisan will be taken for 12 weeks in combination with conventional treatment. Participants in the control group will not take any Kampo medicine; only the standard treatment will be taken. Subsequently, the degree of pain will be assessed, and saliva tests of all the patients on their first visit will be performed. Goreisan will be taken at a dose of 7.5 g/d (minute 3) for 12 consecutive weeks. Twelve weeks later, the degree of pain of each patient will be assessed. DISCUSSION: The purpose of this study is to investigate the efficacy of Goreisan for pain reduction in patients undergoing treatment for glossodynia-related pain. If pain in glossodynia patients can be reduced by the administration of Goreisan, its candidacy as an alternative treatment for pain in glossodynia can be further supported by more reliable research.

trial registrationThe study was registered in the jRCTs071200017. URL https://jrct.niph.go.jp/latest-detail/jRCTs071200017.

Indexed as

Drugs, Chinese HerbalGlossalgiaHumansMedicine, KampoMulticenter Studies as TopicPain ManagementPain MeasurementRandomized Controlled Trials as TopicDrugs, Chinese Herbalgorei-san

Identifiers

PMID32872000
PMCPMC7437797
OpenAlexW3049410780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.